ライフサイエンスコーパス: MMSE

1 MMSE (score and items) did not discriminate patients wit

2 MMSE has been used in hepatology but its usefulness in t

3 MMSE, RPM, AVLT, DS, and BD scores were higher in the AB

4 1.51 points [95% CI, 0.94-2.10]; P < .001), MMSE (mean difference, 0.56 points [95% CI, 0.32-0.80];

5 cline (ADAS_cog, P = 0.011; FAQ, P = 0.0016; MMSE, P = 0.004).

6 vs. post-procedure: 5 [3 to 7], p = 0.002), MMSE (pre-procedure: 27 [25 to 28] vs. post-procedure: 2

7 xicity were IRI arm (odds ratio [OR], 5.03), MMSE </= 27/30 (OR, 3.84), and impaired IADL (OR, 4.67);

8 interaction contributed an additional -0.16 MMSE points per year (95% CI, -0.29 to -0.03; P = .01).

9 e decline attributable to delirium was -0.37 MMSE points per year (95% CI, -0.60 to -0.13; P < .001).

10 e pathologic processes of dementia was -0.39 MMSE points per year (95% CI, -0.57 to -0.22; P < .001).

11 hologic processes of dementia declining 0.72 MMSE points per year faster than age-, sex-, and educati

12 Cognition averaged 0.8 MMSE (mini-mental state examination) points better (95%

13 and 7 patients with Alzheimer disease (AD) (MMSE <19).

14 nd performance on cognitive tests (ADAS_cog, MMSE, and FAQ) was determined with 2 different correlati

15 Combining age, MMSE score, Charlson's comorbidity index, and length of

16 In conclusion, although MMSE score and single items are altered in patients with

17 howed individually divergent results with an MMSE rate of change of -3.2 points per year.

18 .003), PSP (p=0.022) and CBD (p=0.0002); and MMSE in CBD (p=0.004).

19 nt change on CDR-SB (r = 0.42, P < 0.01) and MMSE (r =-0.52, P < 0.01).

20 In the ABC21, folate, vitamin B-12, and MMSE score were positively correlated and homocysteine w

21 (MMSE) score and microglial activation, and MMSE score and rCMRGlc.

22 The domain-composite and MMSE-type global cognitive function z scores both decrea

23 iation between use of psychotropic drugs and MMSE score (p = 0.004) is particularly potent in those c

24 otal score of SOFA (severity of illness) and MMSE (cognitive impairment).

25 correlation was found between VF indices and MMSE or H-Y scores.

26 he change of ipsilateral brain perfusion and MMSE (r = -0.33, p = 0.01) was also identified.

27 On the basis of age, sex, and MMSE score only, the 3-year progression risk to AD demen

28 henotypic sharing between RNFL thickness and MMSE (5%, 95% CI: 0-10%) or RT (7%, 95% CI: 1-12%).

29 he relation between level of alcohol use and MMSE score change between waves 2 and 3 of the study was

30 orrelation with any of MMSE items as well as MMSE summary score.

31 ly tested within 12 months of death (average MMSE 24.2).

32 ms experienced a significant gain in average MMSE score longitudinally over time, with no difference

33 erienced a statistically significant average MMSE score increase over time, with no difference betwee

34 Most patients with an abnormal baseline MMSE score (< 27) experienced significant increases.

35 Patients with an abnormal baseline MMSE were more likely to have an improvement in cognitiv

36 seline MMSE 20-26) and moderate AD (baseline MMSE 15-19) responded differently to tarenflurbil in the

37 evealed that patients with mild AD (baseline MMSE 20-26) and moderate AD (baseline MMSE 15-19) respon

38 Age at onset, baseline MMSE, years of education, motor exam score, sex, depress

39 of aging 5 years in relation to the baseline MMSE score in study data.

40 The BC-MMSE association was greater only among individuals with

41 However, CRP modified the BC-MMSE relationship, with stronger associations only at hi

42 Because MMSE could be impaired in several cognitive dysfunctions

43 n, smoking, alcohol intake, and time between MMSE tests.

44 well with cognitive status as determined by MMSE when the entire cohort of controls and AD patients

45 yme immunoassay, and the cognitive status by MMSE.

46 slightly lower in individuals with decreased MMSE scores.

47 uce the Bayesian minimum mean squared error (MMSE) conditional error estimator and demonstrate its co

48 4) as well as on the mini-mental state exam (MMSE), digit symbol substitution (DSS) test, and a verba

49 airment (MCI) [minimental state examination (MMSE) >/=19], 2 patients with pre-MCI (normal MMSE), and

50 asured by the Mini-Mental State Examination (MMSE) and assessed by observers through the Informant Qu

51 determined by Mini-Mental State Examination (MMSE) and Cambridge Assessment of Mental Health for the

52 ing using the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating scale.

53 standardized Mini-Mental State Examination (MMSE) and memory, processing speed, language, and execut

54 ng tests, the Mini-Mental State Examination (MMSE) and Mini-Cog, administered at hospital discharge,

55 s assessed by Mini-Mental State Examination (MMSE) at baseline and years 1, 2, 3, and 5.

56 alk tests and Mini-Mental State Examination (MMSE) at initial, two-month, and yearly visits.

57 completed the Mini-Mental State Examination (MMSE) at three time points in 1981, 1982, and 1993-1996.

58 completed the Mini-Mental State Examination (MMSE) during three study waves in 1981, 1982, and 1993-1

59 completed the Mini-Mental State Examination (MMSE) in 1991, and at that time, they or caregivers also

60 Mini-Mental State Examination (MMSE) is one of the most commonly used methods in the as

61 sessed by the Mini-Mental State Examination (MMSE) is reported here.

62 i type, and a Mini-Mental State Examination (MMSE) rate of change of +1.8 points per year, whereas pa

63 arameters and Mini-Mental State Examination (MMSE) results.

64 0.009], lower Mini-Mental State Examination (MMSE) score (MMSE, [27 (23-29) vs 28 (27-30) points; P =

65 gender, lower mini-mental state examination (MMSE) score and higher AD assessment scale cognitive sub

66 ation between mini-mental state examination (MMSE) score and microglial activation, and MMSE score an

67 ity who had a mini-mental state examination (MMSE) score of 15-26 were randomly assigned to receive t

68 </= 1 in 75%, Mini-Mental State Examination (MMSE) score was </= 27/30 in 31%, and Instrumental Activ

69 all score and Mini-Mental State Examination (MMSE) score was assessed at baseline and follow-up using

70 (FPI) score, Mini-Mental State Examination (MMSE) score, and handgrip and handheld dynamometer stren

71 Folstein Mini-Mental State Examination (MMSE) scores and neurologic function scores (NFS) at bas

72 subscores and Mini Mental State Examination (MMSE) scores at baseline (analyses of variance, receiver

73 es: Change in Mini-Mental State Examination (MMSE) scores during the 6 years before death.

74 and change in Mini-Mental State Examination (MMSE) scores in the Normative Aging Study, a cohort of e

75 s incapacity, Mini-Mental State Examination (MMSE) scores less than 20 increased the likelihood of in

76 ct changes in Mini-Mental State Examination (MMSE) scores over 24-months using standardized data.

77 and Folstein Mini-Mental State Examination (MMSE) scores recorded at baseline, 6, 12, 18, and 24 mon

78 esveratrol on Mini-Mental State Examination (MMSE) scores, macrophage M1M2 phenotype [the ratio of in

79 nts including Mini-Mental State Examination (MMSE), Alzheimer Disease Assessment Scale-Cognitive subs

80 atteries, the Mini-Mental State Examination (MMSE), and the Montreal Cognitive Assessment (MoCA).

81 ssment (MNA), Mini-Mental State Examination (MMSE), Geriatric Depression Scale (GDS15), and Timed Get

82 rmance by the Mini Mental State Examination (MMSE), National Adult Reading Test (NART), Raven's Progr

83 ormance using Mini Mental State Examination (MMSE), PD staging using modified Hoehn and Yahr (H-Y) sc

84 scores on the Mini-Mental State Examination (MMSE), the Brief Psychiatric Rating Scale, the Scale for

85 ubscales, the Mini-Mental State Examination (MMSE), the HD Activities of Daily Living (ADL) Scale, an

86 sted with the Mini-Mental State Examination (MMSE), the Mattis Dementia Rating Scale, and the Executi

87 (UPSIT), the Mini-Mental State Examination (MMSE), the Mattis Dementia Rating Scale-2 (DRS-2), and t

88 by using the Mini-Mental State Examination (MMSE), the Trail Making Test (TMT) A and B, and the Verb

89 /= 25) on the Mini-Mental State Examination (MMSE), which is a proxy of poor cognition.

90 y of 7 tests: Mini-Mental State Examination (MMSE), word list learning (verbal memory), digit span (a

91 individuals); Mini-Mental State Examination (MMSE)-type tests were available at the end of treatment

92 ally with the mini-mental state examination (MMSE).

93 ing Scale and Mini-Mental State Examination (MMSE).

94 rmance on the Mini-Mental State Examination (MMSE).

95 n measured by Mini-Mental State Examination (MMSE).

96 e severity on Mini Mental State Examination (MMSE).

97 'passed' the Mini-Mental State Examination (MMSE).

98 erformance on mini mental state examination (MMSE, F(5,883) = 5.8, p < 0.001), and with faster reacti

99 scores on the Mini-Mental State Examination (MMSE; -2.4 points over 36 weeks) and the cognitive subsc

100 performance), Mini-Mental State Examination (MMSE; 0 [worst] to 30 [best] points), Clinical Dementia

101 p=0.011) and Mini-Mental State Examination (MMSE; p=0.004) at 1 year; these differences were not pre

102 he use of the Mini-Mental State Examination (MMSE; score range, 0 to 30, with lower scores indicating

103 pression with MiniMental Status Examination (MMSE) and neurofibrillary tangle (NFT) scores across all

104 underwent a Mini-Mental Status Examination (MMSE) for correlation with the whole-brain NAA.

105 er, race and Mini-Mental Status Examination (MMSE) result were not predictive.

106 ted with the mini-mental status examination (MMSE) score.

107 ividuals with MiniMental Status Examination (MMSE) scores lower than 10 were testable by recognition

108 Hourly Mini-Mental Status Examination (MMSE) scores showed an increase during stimulation when

109 AS_cog), the Mini-Mental Status Examination (MMSE), and the Functional Activities Questionnaire (FAQ)

110 t (defined as Mini Mental State Examination [MMSE] </=25) using data from nine cohorts of patients wi

111 10.6 y; mean Mini-Mental State Examination [MMSE] score +/- SD, 22.2 +/- 6.0) or frontotemporal loba

112 th severe AD (mini-mental state examination [MMSE] score 5-12 points), in a nursing home setting were

113 age, sex, and Mini-Mental State Examination [MMSE] score), magnetic resonance imaging (MRI) biomarker

114 and mean [SE] Mini-Mental State Examination [MMSE] score, 28 [0.3]), 61 patients with mild cognitive

115 er's disease (mini-mental state examination [MMSE] scores 10-24) at 11 sites in Russia.

116 the 30-point Mini Mental State Examination [MMSE]), and adverse events.

117 irrhosis underwent neurological examination, MMSE and electroencephalography (EEG).

118 Sequential Mini-Mental State Examinations (MMSE) demonstrated an 80% reduction in new cognitive def

119 s in the proportion of patients experiencing MMSE score decline between the randomized study arms at

120 Geriatric factors (MMSE and IADL) are predictive of severe toxicity or unex

121 re for PACC at baseline was 0.00 (2.60); for MMSE, 29.0 (1.2); for CDR-Sum of Boxes, 0.04 (0.14); and

122 ifferences were found between PD and PSP for MMSE and ACE-R (total score and subscores for attention

123 readmission performance status, IADL, GDS15, MMSE, GUG, and MNA were associated with increased likeli

124 items are altered in patients with overt HE, MMSE has no value in the assessment of minimal HE.

125 iving independently had significantly higher MMSE scores, lower SANS scores, more years of education,

126 vere toxicity or unexpected hospitalization (MMSE) in a randomized prospective phase III study in mCR

127 f Abeta, and are associated with an improved MMSE rate of change in ApoEe3/e3 vs. ApoEe3/e4 patients.

128 -2.7 p = 0.004, MWU Z = -3.0 p = 0.005), in MMSE at one and 52 weeks (MWU Z = -2.9 p = 0.003, MWU Z

129 oncentration was associated with a change in MMSE score of -0.24 (95% confidence interval: -0.44, -0.

130 ge was positively correlated with changes in MMSE and memory scores after 24 months in the drug group

131 The changes in MMSE score in response to the 3 different treatments wer

132 patients experienced significant decline in MMSE score.

133 ifying subjects with significant declines in MMSE scores, and (3) incorporating SNPs of top 10 genes

134 sion, there was significant deterioration in MMSE scores for patients who were to experience progress

135 ion, clinically significant deterioration in MMSE scores was a strong predictor of a more rapid time

136 lly significant difference between groups in MMSE score.

137 No corresponding changes occurred in MMSE scores.

138 Individual MMSE score differences between waves 2 and 3 were calcul

139 Their initial MMSE score of 23.3 (SD=4.2) improved to 26.6 (SD=3.5) at

140 in cognitive function over 2 years (initial MMSE score: mean=26.3, SD=3.1; score at 2-year follow-up

141 95% CI: 1.20, 2.05) times higher odds of low MMSE scores.

142 ypertension, older age, female gender, lower MMSE score and higher ADAS-cog score, had a high risk fo

143 hose who ate more calories in 1976 had lower MMSE scores in 1991 (p = 0.03), an association strengthe

144 Less-educated subjects had lower MMSE scores, especially among the very elderly.

145 ls (CIs) = 20.95 to 23.13; 124 control, mean MMSE = 22.59, 95% CI = 21.58 to 23.6; p = 0.48).

146 rences, the between-group difference in mean MMSE scores was significant 30 days after surgery (P<0.0

147 severity at diagnosis (99 intervention, mean MMSE = 22.04, 95% confidence intervals (CIs) = 20.95 to

148 hose without delirium, both at 1 month (mean MMSE score, 24.1 vs. 27.4; P<0.001) and at 1 year (25.2

149 postoperatively had lower preoperative mean MMSE scores than those in whom delirium did not develop

150 The mean MMSE score 6 years before death was 24.7 points.

151 The mean MMSE score of patients with MCI and pre-MCI was 25.9 at

152 D) (n = 31; age +/- SD, 63.9 +/- 7.1 y, mean MMSE score +/- SD, 23.8 +/- 6.7).

153 The median MMSE score for survivors was within the reference range

154 At baseline, the median MMSE score in patients in both the apolipoprotein E (Apo

155 pulation, including nonsurvivors, the median MMSE score was 14 in the 33 degrees C group (interquarti

156 MSE) >/=19], 2 patients with pre-MCI (normal MMSE), and 7 patients with Alzheimer disease (AD) (MMSE

157 items, MDF showed no correlation with any of MMSE items as well as MMSE summary score.

158 not result in significantly higher rates of MMSE score decline than RT alone through 5 years of foll

159 HE and with overt HE were seen in respect of MMSE score (p<0.02), orientation to place (p<0.003), rep

160 of the study was to investigate the value of MMSE in detection of HE in patients with cirrhosis.

161 95% confidence interval (CI) -0.06-0.02) or MMSE score (0.06, 95% CI -0.002-0.12).

162 nce, 2.4 [95% CI, -1.2 to 6.0], P = .19), or MMSE score (difference, 0.6 [95% CI, -0.2 to 1.4], P = .

163 diovascular Society Angina Classification or MMSE scores.

164 ive function especially the primary outcomes MMSE and episodic memory with Bushen capsule treatment.

165 o cerebellum FDG metabolism ratios predicted MMSE (beta=0.38, p=0.001) and MoCA (beta=0.3, p=0.002) a

166 stimulation when compared to prestimulation MMSE, largely due to improvement in recall, possibly rep

167 ementia (mini-mental state examination score MMSE=23), mean yearly loss of brain volume was 2.8% (95%

168 Mini-Mental State Examination (MMSE) score (MMSE, [27 (23-29) vs 28 (27-30) points; P = 0.021], leng

169 age, 65 [1] years; 45% female; and mean [SE] MMSE score, 22 [0.7]).

170 age, 68 [1] years; 38% female; and mean [SE] MMSE score, 27 [0.3]), and 65 patients with AD (mean [SE

171 under ROC of 0.814 in predicting significant MMSE decline: our model has 100% precision at 5% recall,

172 ross only control and incipient AD subjects (MMSE > 20).

173 Test performance analysis has shown that MMSE has no value as a prediction method in determining

174 The MMSE is a relatively insensitive tool, and subtle change

175 The MMSE is useful only at extreme scores.

176 The MMSE rate of change increased in the ApoE epsilon3/epsil

177 d greater declines in verbal fluency and the MMSE (P < 0.05).

178 ven patients (39%) were impaired on both the MMSE and Mini-Cog, whereas only 20 patients (28%) had sc

179 ad cognitive impairments, as assessed by the MMSE and Mini-Cog, at hospital discharge.

180 op in cognitive function (as measured by the MMSE score) 2 days after surgery than did those without

181 al cognitive performance, as assessed by the MMSE score.

182 after focal radiotherapy as measured by the MMSE.

183 eventy critically ill patients completed the MMSE and Mini-Cog just before hospital discharge.

184 th a rate of decline slightly slower for the MMSE (0.004 SD/decade less, 95% CI [0.002, 0.006], p = 0

185 However, the MMSE and Mini-Cog scores did not predict long-term cogni

186 le cases of incident dementia (a fall in the MMSE score to <24 points or a drop of three points in 1

187 The adjusted difference in the MMSE score was -0.90 (95% CI: -1.6, -0.19; P for trend =

188 n multiple cognitive measures, including the MMSE, the cognitive subscale of the Brief Psychiatric Ra

189 regression analyses showed that neither the MMSE nor the Mini-Cog predicted cognitive sequelae at 6

190 ive decline not apparent with the use of the MMSE.

191 w the mean of the comparison subjects on the MMSE (N=8, 44%) and the Mattis Dementia Rating Scale tot

192 tients (64%) had impaired performance on the MMSE (score < 27, mean = 24.4) and 32 (45%) on the Mini-

193 scores declined a mean of 1.20 points on the MMSE (standard deviation 1.90), with 66% having scores t

194 Males declined on the MMSE at a slightly slower rate than females (difference

195 a slightly faster decline (p = 0.021) on the MMSE for Asians (-0.20 SD/decade, 95% CI [-0.28, -0.12],

196 We examined performance on the MMSE in the first year after surgery, controlling for de

197 eper decline over time in performance on the MMSE test among nonoccupationally exposed elderly men.

198 7.4 (standard deviation, 6.6) years took the MMSE on two occasions that were an average of 3.5 (stand

199 subsequent cognitive decline rated with the MMSE and MoCA.

200 ed cognitive impairment as measured with the MMSE and the Clinical Dementia Rating scale sum-of-boxes

201 A change of more than three MMSE points was considered clinically significant.

202 o had no significant effect on end-treatment MMSE-type global cognitive function (z score difference:

203 he TYM-MCI, the Test Your Memory test (TYM), MMSE and revised Addenbrooke's Cognitive Examination (AC

204 la were significantly correlated with UPSIT, MMSE, DRS-2, and CDR scores.

205 , overt HE (West-Haven criteria) and various MMSE items, MDF showed no correlation with any of MMSE i

206 ization, significant predictive factors were MMSE </= 27/30 (OR, 4.56) and Geriatric Depression Scale

207 whole-brain NAA loss was detected even when MMSE scores were unchanged, the former seems to be a mor

208 r combinations of parameters associated with MMSE could help provide better group discrimination.

209 When a comparison with MMSE scores was made, (18)F-FDG significantly correlated

210 volume and hippocampal were correlated with MMSE results.

211 betapir scores significantly correlated with MMSE scores only when both controls and AD patients were

212 ade, (18)F-FDG significantly correlated with MMSE when both controls and AD patients were included (r

213 munoreactive neurons was not correlated with MMSE, age at death, education, apolipoprotein E allele s

214 but some evidence of a weak correlation with MMSE (r =-0.22, P = 0.09).

215 gender, but had an inverse correlation with MMSE score.

216 om 26% (95% CI, 19%-34%) in younger men with MMSE scores of 29 to 76% (95% CI, 65%-84%) in older wome

217 associated neither with each other nor with MMSE.

218 235 patients with MMSE </=25 at baseline and 135 whose first study visit o

219 Neuropsychological tests with MMSE and episodic memory as the primary outcomes and res

220 to 76% (95% CI, 65%-84%) in older women with MMSE scores of 24 (1-year risk: 6% [95% CI, 4%-9%] to 24

221 d 66 control subjects (age = 73.5+/-7.3 yrs; MMSE = 29+/-1.3) from the Australian Imaging Biomarkers